Publications

2011
Other Unpublished Work

From Farms to Fuel Tanks: Collective Actors and New-Venture Innovation in the U.S. Biodiesel Fuel Sector

By: Shon R. Hiatt

Little is known about the influence of collective actors on innovative technological recombinations by new ventures. Using data from U.S. biodiesel producers, I examine how the efforts of multiple collective actors (farm associations) to promote varying types of... View Details

Keywords: Alliances; Agribusiness; Energy Sources; Innovation and Invention; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; United States

January 2017 (Revised March 2017)
Case

Royal DSM: From Continuous Transformation to Organic Growth

By: William W. George, Carin-Isabel Knoop and Amram Migdal

Royal DSM CEO Feike Sijbesma was pondering the challenges of shifting DSM’s global organization from the constant transformations of the past 100 years to creating organic growth. When Sijbesma took the helm as CEO in 2007, he further pushed and completed the company’s... View Details

Keywords: Organic Growth; Organizational Change; M＆A; Mergers And Acquisitions; Divestment; Business Ventures; Business Divisions; Business Growth and Maturation; Restructuring; Change; Change Management; Transformation; Transition; Engineering; Chemicals; Mining; Ethics; Values and Beliefs; Finance; Capital Markets; Financial Markets; Food; Globalization; Global Strategy; Globalized Firms and Management; Globalized Markets and Industries; Health; Nutrition; History; Leadership; Leadership Development; Leadership Style; Leading Change; Management; Business or Company Management; Growth and Development Strategy; Growth Management; Management Practices and Processes; Management Style; Organizations; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Change and Adaptation; Organizational Culture; Organizational Design; Ownership; Public Ownership; Performance; Strategy; Adaptation; Consolidation; Corporate Strategy; Value; Value Creation; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Europe; Netherlands

11 Sep 2007
First Look

First Look: September 11, 2007

and deliverables. Many critical business challenges are detailed in this case. Nevertheless, given their fully integrated business model and significant manufacturing base, the odds are in Biocon's favor to overcome these challenges and lead India's View Details

Keywords: Martha Lagace

12 Oct 1999
Research & Ideas

Porter’s Perspective: Competing in the Global Economy

you decide to put together this collection of articles? Porter: In retrospect, my work divides into three major areas. The first has to do with how firms compete in industries and gain competitive advantage. The next focuses on locations... View Details

Keywords: Re: Michael E. Porter

September 2024
Case

Myeloma Investment Fund

By: Kyle Myers and Scott Sawaya

This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.

The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details

Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry

November 2014
Teaching Note

Claritas Genomics

By: Robert F. Higgins and Matthew G. Preble

Dr. Patrice Milos is the first CEO of Claritas Genomics (Claritas) and she faces a number of challenges in scaling the young company. Claritas was formed around a lab spun out from Boston Children's Hospital (BCH) which had performed genomic tests for the hospital. Now... View Details

Keywords: Healthcare; Healthcare Startups; Genetic Testing; Genetics Diagnostics; Spinning Out Hospital Services; Spin-out; Health Care and Treatment; Genetics; Entrepreneurship; Biotechnology Industry; Biotechnology Industry; United States

September 2014
Case

Pfizer's Centers for Therapeutic Innovation (CTI)

By: Gary Pisano, James Weber and Kait Szydlowski

In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details

Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; Asia

December 2010
Teaching Note

Roche's Acquisition of Genentech (TN)

By: Bo Becker and Carliss Y. Baldwin

Teaching Note for 210-040. View Details

Keywords: Mergers and Acquisitions; Stock Shares; Opportunities; Strategy; Organizational Culture; Value; Negotiation Tactics; Biotechnology Industry; Biotechnology Industry

November 2009
Case

The Explosion of Genetic Testing: Opportunities and Challenges

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details

Keywords: Genetics; Health Care and Treatment; Health Testing and Trials; Disruptive Innovation; Business Model; Biotechnology Industry; Biotechnology Industry

October 2009 (Revised July 2013)
Case

Gilead Sciences, Inc.: Access Program

By: V. Kasturi Rangan and Katharine Lee

Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details

Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Biotechnology Industry

June 2008
Case

Gordon Williams: Clinical Research at Brigham and Women's Hospital

By: H. Kent Bowen and Courtney Purrington

Clinical research is a critical element of biomedical research and development. This case describes the challenges of clinical research, and its role in bringing breakthroughs to patients. Dr. Williams leads through his own research and special programs to train... View Details

Keywords: Training; Health Care and Treatment; Success; Programs; Research and Development; Biotechnology Industry; Biotechnology Industry

Find at Harvard

June 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (D)

By: Sandra J. Sucher and Stacy McManus

Supplements the (A) and (B) cases. View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry

September 2012 (Revised September 2012)
Course Overview Note

Building Life Science Businesses Fall 2012: Course Outline and Syllabus

By: Richard G. Hamermesh and Richard G. Hamermesh

This Course Outline and Syllabus gives an overview of the Fall 2012 class Building Life Science Businesses View Details

Keywords: Healthcare Ventures; Entrepreneurial Management; Entrepreneurship; Entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Health Industry; Health Industry; Health Industry; Asia; North America; Europe

06 Jun 2017
First Look

First Look at New Research and Ideas: June 6, 2017

modern industrial corporation encompasses a myriad of different software applications, which must work in concert to deliver functionality to end users. However, the increasingly complex and dynamic nature of competition in today’s... View Details

Keywords: Sean Silverthorne

18 Dec 2012
First Look

First Look: December 18

assumptions are present in the structure of technology and labor flows within Silicon Valley and its surrounding areas. Our model further identifies how the lengths over which agglomerative forces operate influence the shapes and sizes of View Details

Keywords: Carmen Nobel

06 Mar 2012
First Look

First Look: March 6

influential, and industry less influential, than we commonly assume. How Early Adoption Has Increased Wealth—Until Now Authors:Diego Comin and Bart Hobijn Publication:Harvard Business Review 90, no. 3 (March 2012) Abstract Societies that... View Details

Keywords: Sean Silverthorne

August 2013
Course Overview Note

Building Life Science Businesses Fall 2013: Course Outline and Syllabus

By: Richard G. Hamermesh

This Course Outline and Syllabus gives an overview of the Fall 2013 class Building Life Science Businesses. View Details

Keywords: Healthcare Ventures; Entrepreneurial Management; Entrepreneurship; Entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Health Industry; Health Industry; Health Industry; Asia; North America; Europe

April 2024 (Revised November 2024)
Case

Moderna: Pioneering a People Platform to Accelerate Science Innovation

By: Tatiana Sandino, Emil Dy and Samuel Grad

Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details

Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Pharmaceutical Industry; Pharmaceutical Industry; United States

November 2020
Teaching Note

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher

Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details

Keywords: Mergers and Acquisitions; Valuation; Value; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States